Robert Chess Sells 3,504 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess sold 3,504 shares of the company’s stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $51.85, for a total transaction of $181,682.40. Following the sale, the director now directly owns 21,641 shares in the company, valued at $1,122,085.85. This trade represents a 13.94 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Robert Chess also recently made the following trade(s):

• On Monday, November 11th, Robert Chess sold 3,600 shares of Twist Bioscience stock. The stock was sold at an average price of $47.26, for a total value of $170,136.00.

Twist Bioscience Price Performance

Shares of NASDAQ TWST traded down $0.94 during mid-day trading on Monday, reaching $47.23. 457,416 shares of the company’s stock were exchanged, compared to its average volume of 937,404. Twist Bioscience Co. has a 52 week low of $27.41 and a 52 week high of $60.90. The firm has a 50-day moving average price of $45.61 and a two-hundred day moving average price of $46.65. The firm has a market capitalization of $2.80 billion, a price-to-earnings ratio of -13.12 and a beta of 1.82.

Institutional Investors Weigh In On Twist Bioscience

Several large investors have recently modified their holdings of TWST. Caprock Group LLC lifted its stake in Twist Bioscience by 2.9% in the 2nd quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock worth $387,000 after purchasing an additional 220 shares in the last quarter. Signaturefd LLC grew its position in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after acquiring an additional 306 shares during the last quarter. Arizona State Retirement System raised its stake in shares of Twist Bioscience by 1.9% during the second quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock worth $798,000 after acquiring an additional 308 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of Twist Bioscience by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock worth $457,000 after acquiring an additional 312 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Twist Bioscience by 2.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company’s stock valued at $734,000 after purchasing an additional 363 shares in the last quarter.

Analysts Set New Price Targets

TWST has been the topic of a number of research reports. Evercore ISI boosted their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Robert W. Baird raised their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research note on Tuesday, November 19th. Scotiabank raised their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research report on Tuesday, November 19th. Leerink Partners boosted their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. Finally, Wolfe Research began coverage on Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.90.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.